September 18th 2024
Your daily dose of the clinical news you may have missed.
September 17th 2024
New data shows that favorable CV health in the first trimester is associated with a 35% to 62% lower risk of HDP regardless of level of genetic risk.
September 13th 2024
Unawareness was highest among the youngest adults, aged 18 to 44 years, an age range where CV health should be optimized to avoid later morbidity, researchers wrote.
Approximately 10.5 million US adults, or 5% of the population, have the atrial fibrillation, according to new prevalence estimates.
September 12th 2024
AHA Defines Cardiovascular-Kidney-Metabolic Syndrome, Redefines CVD Risk, Prevention, Management
A new paradigm for reducing CV morbidity and mortality provides a comprehensive approach to comorbid metabolic disease including early detection and treatment.
Obesity Before, During Pregnancy Key to Future Cardiovascular Risk, New Research Suggests
A novel study strongly suggests that pre-pregnancy obesity rather than associated adverse pregnancy outcomes is the "culprit" in postpartum heart disease.
GLP-1 Mimetic Semaglutide Is Effective Across Ejection Fraction in Patients with HFpEF and Obesity: New STEP-HFpEF Analysis
Semaglutide treatment reduced weight and was associated with greater, more consistent improvements in HFpEF than other recently studied drug classes.
Daily Dose: Experimental Nasal Spray Found Effective and Safe for Treating Rapid Heartbeat
Daily Dose: Walking More Reduced BP in Sedentary Older Adults with Hypertension
Daily Dose: Biosimilar Liraglutide Found Safe, Effective for Use in Patients with T2D
Daily Dose: Waist-to-Hip Ratio Better Predictor for Mortality than BMI?
One or More Cardiac, Renal, or Metabolic Conditions Affect 25% of US Adults
The prevalence of cardiac, renal, and metabolic conditions has significantly increased over 20 years and so has the number of US adults who have all 3.
Adding 3000 Ordinary Steps/Day Reduced BP in Sedentary Older Adults with Hypertension
An e-health lifestyle walking intervention partially supported by remote coaching led to significant improvement in BP in older adults as well as a desire to keep walking.
Investigational Nasal Spray Found Safe, Effective for Self-Treatment of Paroxysmal Supraventricular Tachycardia
Etripamil 70 mg nasal spray restored heart rate within 30 minutes in approximately 60% of PSVT episodes, report authors of new study.
10 Questions on Adult Blood Pressure Targets Based on AAFP Guidelines
The 2022 AAFP Clinical Practice Guideline on hypertension treatment in adults is the subject matter for this 10-question topline quiz that is also a good source of review.
GLP-1 Mimetics, SGLT-2 Inhibitors Understudied in Black Populations in Pivotal Trials, Benefits Questioned
Pivotal cardiovascular outcome trials that evaluated cardiorenal benefits of the newer classes were not designed to consider racial/ethnic variations, researchers state.
Biosimilar Liraglutide Noninferior to Reference Product in Persons with Type 2 Diabetes: Phase 3 Trial
The biosimilar to the GLP-1 mimetic Victoza proved noninferior for reduction of HbA1c and had similar positive effects on body weight, lipids, and blood pressure.
Empagliflozin Wins FDA Approval for the Treatment of Adults with CKD
Empagliflozin is approved to lower the risk of sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with CKD at risk of progression.
Daily Dose: Antihypertensive Treatment Throughout Late Life Lowers Risk of Dementia
Waist-to-Hip Ratio More Consistently Associated with Mortality vs BMI: New Research
Waist-to-hip ratio was more powerfully and consistently associated with risk of all-cause mortality than BMI or FMI, but can it replace BMI as a clinical indicator?
USPSTF Publishes Final Guidance on Screening for Hypertensive Disorders of Pregnancy
The USPSTF recommends that BP be checked at all prenatal visits for all pregnant persons and calls for reducing vast inequities in maternal health care.
Daily Dose: Efficacy of a Remote Bilingual Program in Reducing Uncontrolled HTN
Novel Factor XI Inhibitor Abelacimab Found Superior to Rivaroxaban in Phase 2b Trial with High-Risk Cohort
The AZALEA-TIMI 71 trial was stopped early due to an "overwhelming reduction" in a composite endpoint of major bleeding events compared to rivaroxaban standard of care.
Antihypertensive Treatment Throughout Late Life May Reduce Risk of Dementia
Results from a new study show that older adults with untreated hypertension had a 42% increased risk of dementia vs healthy controls.
Daily Dose: High Blood Pressure While Lying Down Raises Risk for CVD Events
Daily Dose: "Night Owls" Less Healthy, at Higher Risk for T2D
Daily Dose: More Steps a Day Linked to Better Health for Patients with Heart Failure
Your daily dose of clinical news you may have missed.
Blood Pressure Treatment Targets in Adults with Hypertension: A Guideline Topline
This guideline topline summary of recommendations for treating hypertension in adults is adapted from the American Academy of Family Physicians clinical guideline.
Lorundrostat Phase 2 Trial Results Suggest Potential Efficacy Against Uncontrolled and Resistant Hypertension
The selective aldosterone synthase inhibitor will move into late stage clinical trials, a nod to the potential for a first-in-class agent targeting aldosterone.
Rise in GLP-1 Mimetic Demand Will Continue as Pluripotency Expands
The class of GLP-1 receptor agonists and similar agents, originally approved to treat type 2 diabetes, also reduce body weight and reduce CVD risk; what's next?
Evening Chronotype in Women Linked with Unhealthy Lifestyle, Increased Risk for Type 2 Diabetes
Women with an evening vs morning chronotype were 54% more likely to have unhealthy lifestyles that in turn accounted for a significant increased risk for diabetes.
Remote Bilingual Program Proves Effective in Controlling Blood Pressure in Underserved Population
New research presented at Hypertension 2023 showed a novel digital bilingual hypertension control program improved BP control rates by more than 30%.
Daily Dose: Worldwide Burden of Atrial Fibrillation Doubled Over 30 Years
Hypertension While Lying Down Linked to Elevated Risk for CVD Events
Persons with HTN while in a supine position had a higher risk for CVD even if they did not have HTN while seated, according to new research presented at Hypertension 2023.